Therapeutic area intelligence for Neuroendocrine Tumors with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Phase →

Surufatinib →

Recent signals(2)

ClinicalJuly 29, 2026

Phase Ib Trial of M3814 with Lutetium Lu 177 Dotatate for Pancreatic Neuroendocrine Tumors

A phase Ib trial is investigating the combination of peposertib and lutetium Lu 177 dotatate for treating pancreatic neuroendocrine tumors.

ClinicalJune 12, 2026

Surufatinib trial initiated for adjuvant therapy in pancreatic neuroendocrine tumors

A randomized trial is underway to evaluate surufatinib as adjuvant therapy for pancreatic neuroendocrine tumors.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.